DUBLIN, Sept. 21, 2015 /PRNewswire/ -- Allergan plc,
(NYSE: AGN), a leading global pharmaceutical company, today
announced a nationwide partnership with the Caregiver Action
Network (CAN), the nation's leading family caregiver organization,
to provide thank you meals to 1,000 family caregivers across the
country through a new initiative called Take 1 Moment.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Family caregiving is an enormous and growing issue in our
country. Last year caregivers provided an estimated 17.9 billion
hours of unpaid care, a contribution to the nation valued at
$217.7 billion.
"On World Alzheimer's Day, we are extending our commitment to be
there for families and loved ones living day-to-day with
Alzheimer's through initiatives like Take 1 Moment," said
Gavin Corcoran, MD, Chief Medical
Officer. "We support the campaign's efforts to ease the burden on
caregivers. We also remain committed to offering new therapeutic
options for those with Alzheimer's disease, such as
NAMZARIC."
Approximately 50 percent of people aged 85 and older have
Alzheimer's disease. According to the Alzheimer's Association, by
mid-century someone will develop Alzheimer's every 33 seconds and
there will be nearly a million new cases per year.
The campaign asks people to #Take1Moment to share a memory or
picture of someone they know or knew with Alzheimer's disease on
Facebook, Twitter, Instagram or Pinterest. For the first 1,000
hashtags, the campaign will provide a thank you meal from Chef'd, a
gourmet, fresh ingredient meal-kit delivery service, to a caregiver
identified by CAN.
To learn more about #Take1Moment, visit the Caregiver Action
Network website www.caregiveraction.org, which also has additional
resources for Alzheimer's disease caregivers.
About NAMZARIC
NAMZARIC is a fixed-dose combination (FDC) of memantine
hydrochloride extended-release, a NMDA receptor antagonist, and
donepezil hydrochloride, an acetylcholinesterase inhibitor.
Namzaric was approved for the treatment of moderate to severe
dementia of the Alzheimer's type in patients stabilized on certain
doses of memantine hydrochloride and donepezil hydrochloride.
To learn more about a new treatment option that might be right
for your loved one, visit Namzaric.com.
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Allergan Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the risks associated with acquisition
transactions; the difficulty of predicting the timing or outcome of
FDA approvals or actions, if any; the impact of competitive
products and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Quarterly Report on Form
10-Q for the quarter ended March 31,
2015 (such periodic public filings having been filed under
the "Actavis plc" name) and from time to time in Allergan's other
investor communications . Except as expressly required by law,
Allergan disclaims any intent or obligation to update these
forward-looking statements.
CONTACTS:
Investors:
Lisa
DeFrancesco
(862) 261-7152
Media:
Mark Marmur
862-261-7558
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-supports-world-alzheimers-disease-day-by-giving-back-300146212.html
SOURCE Allergan plc